EA202090193A1 - Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида - Google Patents
Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамидаInfo
- Publication number
- EA202090193A1 EA202090193A1 EA202090193A EA202090193A EA202090193A1 EA 202090193 A1 EA202090193 A1 EA 202090193A1 EA 202090193 A EA202090193 A EA 202090193A EA 202090193 A EA202090193 A EA 202090193A EA 202090193 A1 EA202090193 A1 EA 202090193A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystal form
- crystalline forms
- type calcium
- trifluoromethylcyclopropyl
- cyanopyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 | ||
| PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090193A1 true EA202090193A1 (ru) | 2020-06-03 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090193A EA202090193A1 (ru) | 2017-07-05 | 2018-07-04 | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (enExample) |
| EP (1) | EP3649117B1 (enExample) |
| JP (2) | JP2020525475A (enExample) |
| KR (1) | KR102645911B1 (enExample) |
| CN (1) | CN110831932A (enExample) |
| AU (1) | AU2018296423B2 (enExample) |
| BR (1) | BR112020000099A2 (enExample) |
| CA (1) | CA3067489A1 (enExample) |
| CL (1) | CL2020000002A1 (enExample) |
| EA (1) | EA202090193A1 (enExample) |
| IL (1) | IL271764B2 (enExample) |
| MA (1) | MA50972A (enExample) |
| MY (1) | MY206357A (enExample) |
| PH (1) | PH12020500040A1 (enExample) |
| SG (1) | SG11201912881SA (enExample) |
| UA (1) | UA126582C2 (enExample) |
| WO (1) | WO2019008034A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
| US20230047102A1 (en) | 2019-12-20 | 2023-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| CN118202050A (zh) * | 2021-08-17 | 2024-06-14 | 韩国科学技术院 | 靶向cav3.1基因的反义寡核苷酸及其用途 |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| JP6500092B2 (ja) | 2014-09-15 | 2019-04-10 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物 |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
-
2018
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active Active
- 2018-07-04 EP EP18749304.4A patent/EP3649117B1/en active Active
- 2018-07-04 MY MYPI2020000011A patent/MY206357A/en unknown
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en not_active Ceased
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11555025B2 (en) | 2023-01-17 |
| UA126582C2 (uk) | 2022-11-02 |
| BR112020000099A2 (pt) | 2020-07-07 |
| WO2019008034A1 (en) | 2019-01-10 |
| SG11201912881SA (en) | 2020-01-30 |
| JP2023123679A (ja) | 2023-09-05 |
| MA50972A (fr) | 2020-10-14 |
| US20200165221A1 (en) | 2020-05-28 |
| US11059803B2 (en) | 2021-07-13 |
| MY206357A (en) | 2024-12-12 |
| JP2020525475A (ja) | 2020-08-27 |
| CN110831932A (zh) | 2020-02-21 |
| IL271764B1 (en) | 2023-06-01 |
| IL271764A (en) | 2020-02-27 |
| EP3649117B1 (en) | 2024-10-09 |
| CA3067489A1 (en) | 2019-01-10 |
| KR102645911B1 (ko) | 2024-03-08 |
| CL2020000002A1 (es) | 2020-07-31 |
| US20210300894A1 (en) | 2021-09-30 |
| KR20200018698A (ko) | 2020-02-19 |
| PH12020500040A1 (en) | 2020-10-12 |
| IL271764B2 (en) | 2023-10-01 |
| AU2018296423A1 (en) | 2020-02-20 |
| AU2018296423B2 (en) | 2022-07-28 |
| EP3649117A1 (en) | 2020-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090193A1 (ru) | Кристаллическая форма n-[1-(5-цианопиридин-2-илметил)-1h-пиразол-3-ил]-2-[4-(1-трифторметилциклопропил)фенил]ацетамида | |
| EP4143305A4 (en) | GENETICALLY MODIFIED CENTRAL NERVOUS SYSTEM COMPOSITIONS | |
| MX2010004530A (es) | Antagonistas de los canales de calcio tipo t de heterociclo fenil amida. | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201490922A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| EA201692049A1 (ru) | Гетероарилзамещенные гетероциклилсульфоны | |
| EA201692007A1 (ru) | Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений | |
| EA201790892A1 (ru) | Кристаллические формы 5-хлор-n4-[2-(диметилфосфорил)фенил]-n2-{2-метокси-4-[4-(4-метилпиперазин-1-ил)пиперидин-1-ил]}пиримидин-2,4-диамина | |
| PE20170129A1 (es) | Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201892407A1 (ru) | Кристаллические формы n-[2-(3-гидрокси-3-метилбутил)-6-(2-гидроксипропан-2-ил)-2н-индазол-5-ил]-6-(трифторметил)пиридин-2-карбоксамида | |
| EP3630102C0 (en) | FORMULATIONS FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
| EA201991428A1 (ru) | Фармацевтическая комбинация, содержащая блокатор кальциевых каналов т-типа | |
| EA202192320A1 (ru) | Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-[2-(трифторметил)пиридин-4-ил]-1h-пиразол-4-карбоксамида | |
| EA201692474A1 (ru) | Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2 | |
| EP3655036C0 (en) | COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS | |
| EP3573620A4 (en) | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | |
| EA202091428A1 (ru) | Замещенные амиды ii пирролидина | |
| PL3886799T3 (pl) | Kompozycje do leczenia utraty włosów | |
| EA202091429A1 (ru) | Замещенные амиды i пирролидина | |
| CY1124056T1 (el) | Κρυσταλλικες μορφες της μηλεϊνικης 1-((2r, 4r)-2-(1η-βενζο[d] iμιδαζολ-2-υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας | |
| ATE527243T1 (de) | Calciumkanal-antagonisten vom typ chinazolinon t | |
| EA201691544A1 (ru) | Твердые формы 2-(трет-бутиламино)-4-((1r,3r,4r)-3-гидрокси-4-метилциклогексиламино)пиримидин-5-карбоксамида, его композиции и способы его применения | |
| EP4096675C0 (en) | COMPOSITIONS FOR THE TREATMENT OF LONG COVID | |
| EP3993796C0 (en) | COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM |